Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jun 15, 2021 9:33pm
246 Views
Post# 33393553

RE:RE:RE:Dr. Lilge OSA Webinar - Aug. 18

RE:RE:RE:Dr. Lilge OSA Webinar - Aug. 18
Eoganacht wrote: It's hard to know exactly how this is going to progress. Systemic instillation followed by precision PDT with NIR light in conjunction with low level X-ray irradiation is one option that has been talked about. There is also the possibility they will use nanoparticles to down-convert some X-ray photons to visible light photons. Dr. McFarland has talked about this possibility. Whatever they end up doing they will not likely kill all of the cancer cells with the treatment, which is why it's so important that the procedure induces immunogenic cell death which is critical for antitumour immunity.

CancerSlayer wrote:

Thanks Eoganacht....

Organometallic medicine/PDT is certainly proving its worth....and to think that a single compound (TLD-1433/Rutherrin) could potentially impact human disease in so many ways (cancer, viral/bacterial/fungal/parasitic diseases) is an absolute wonder.  I think its real value will arise from its versatility.

Dr. Lilge's work re: personalized/precision PDT should also help towards defeating some of the more fastidious cancers.  However, it's hard not to appreciate the simple elegance in TLD-1433's mechanism of action/versatility that enables it to broaden its kill zone irrespective of cancer or viral type.  Furthermore, its potential to perform without the need for precision PDT (I.e. using lower-dose external radiation/x-ray, or possibly used independently in the case of viral disease) is what makes this investment even more exciting....JMHO.  Good luck...




 

Well stated & yes...I imagine they may use all of the ACT armamentarium at their disposal to maximize a successful outcome....systemic Rutherrin with low-dose radiation/x-ray, followed by intra-operative/targeted PDT...with the hopes of stimulating a maximal immunogenic response.  And yes, nano scintillation shows great promise & comes in various human-friendly forms....topic for another day.  TLT has built quite the scientific team!

<< Previous
Bullboard Posts
Next >>